1313877-46-1

Basic information

• Product Name: 3,5-bis(4-fluorobenzylidene)-1-[(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)carbonyl]piperidin-4-one
• Synonyms: 3,5-bis(4-fluorobenzylidene)-1-[(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)carbonyl]piperidin-4-one
• CAS NO: 1313877-46-1
• Molecular Weight: 477.531
• Mol File: 1313877-46-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3,5-bis(4-fluorobenzylidene)-1-[(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)carbonyl]piperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-bis(4-fluorobenzylidene)-1-[(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)carbonyl]piperidin-4-one(1313877-46-1)
• EPA Substance Registry System: 3,5-bis(4-fluorobenzylidene)-1-[(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)carbonyl]piperidin-4-one(1313877-46-1)

Safety Data

• Hazardous Substances Data: 1313877-46-1(Hazardous Substances Data)

Upstream product

• 1260791-10-3 (3E,5E)-3,5-bis(4-fluorobenzylidene)-4-piperidone hydrochloride 
• 13810-21-4 2,2,5,5-tetramethyl-pyrrolidinyl-1-oxyl-3-carboxylic acid chloride 

Relevant articles and documents

Synthesis of N-substituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity

A series of 3,5-bis(arylidene)-4-piperidone (DAP) compounds are considered as synthetic analogues of curcumin for anticancer properties. We performed structure-activity relationship studies by synthesizing a number of DAPs N-alkylated or acylated with nitroxides or their amine precursors as potent antioxidant moieties. Both subtituents on arylidene rings and on piperidone nitrogen (five- or six-membered, 2- or 3-substituted or 3,4-disubstituted isoindoline nitroxides) were varied. The anticancer efficacy of the new DAP compounds was tested by measuring their cytotoxicity to cancer cell lines A2780 and MCF-7 and to the H9c2 cell line. The results showed that all DAP compounds induced a significant loss of cell viability in the human cancer cell lines tested; however, only pyrroline appended nitroxides (5c (Selvendiran, K.; Tong, L.; Bratasz, A.; Kuppusamy, L. M.; Ahmed, S.; Ravi, Y.; Trigg, N. J.; Rivera, B. K.; Kálai, T.; Hideg, K.; Kuppusamy, P.Mol. Cancer Ther. 2010, 9, 1169-1179), 5e, 7, 9) showed limited toxicity toward noncancerous cell lines. Computer docking simulations support the biological activity tested. These results suggest that antioxidant-conjugated DAPs will be useful as a safe and effective anticancer agent for cancer therapy.